---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-26-000017"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2026-04-09T23:59:59+00:00"
generated_at: "2026-05-15T06:48:04.718337+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Zentalis selects 400mg QD 5:2 azenosertib monotherapy as pivotal dose for Cyclin E1-positive ovarian cancer

## Summary
- Pre-specified interim analysis from DENALI Part 2a showed clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles.
- New DENALI Part 2c cohort to include ~40 patients previously treated with taxane-containing regimen for PROC, enrollment expected Q2 2026.
- Company expects to complete enrollment in all DENALI Part 2 cohorts and provide topline readout by year-end 2026.
- Azenosertib therapeutic profile supports advancement into confirmatory ASPENOVA Phase 3 trial and pre-commercial activities.

## SEC filing metadata
- accession: 0001725160-26-000017
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2026-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000017/0001725160-26-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000017/zntl-20260409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-26-000017
- JSON: https://secwatch.observer/filing/0001725160-26-000017.json
- Plain text: https://secwatch.observer/filing/0001725160-26-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.